Despite the observed convergence in therapeutic strategies—such as the use of classical anti-apoptotic agents (e.g., targeting the BCL-2 family of proteins) as senolytics—it is crucial to recognize that the underlying survival mechanisms in established tumor cells and SnCs are fundamentally distinct. Here, BCL2 is linked to neoplasm.